(Q35811323)

10 August 2017

title

Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond (English)

1 reference

10 August 2017

main subject

Gram-negative bacteria

0 references

1 reference

Daniel P Boyle

1

1 reference

10 August 2017

Teresa R Zembower

series ordinal

2

1 reference

10 August 2017

language of work or name

1 reference

15 July 2015

1 reference

Urologic Clinics of North America

10 August 2017

published in

1 reference

10 August 2017

volume

42

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

493-505

1 reference

Antibiotic resistance-the need for global solutions

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Extended-spectrum beta-lactamases: a clinical update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Broad-spectrum, transmissible beta-lactamases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

7 January 2021

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Comparative analysis of ESBL-positive Escherichia coli isolates from animals and humans from the UK, The Netherlands and Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Food reservoir for Escherichia coli causing urinary tract infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

ESBL-positive Enterobacteria isolates in drinking water

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Sharing of Escherichia coli sequence type ST131 and other multidrug-resistant and Urovirulent E. coli strains among dogs and cats within a household

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

A step closer to extreme drug resistance (XDR) in gram-negative bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Carbapenemases: the versatile beta-lactamases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

"Nightmare" bacteria on the rise in US hospitals, long-term care facilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Global spread of Carbapenemase-producing Enterobacteriaceae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Current control and treatment of multidrug-resistant Acinetobacter baumannii infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Community-acquired Acinetobacter infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

The epidemiology and control of Acinetobacter baumannii in health care facilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Pseudomonas aeruginosa: a formidable and ever-present adversary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Infection Reduction Strategies Including Antibiotic Stewardship Protocols in Surgical and Trauma Intensive Care Units Are Associated with Reduced Resistant Gram-Negative Healthcare-Associated Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.05.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UCL.2015.05.005

1 reference

10 August 2017

1 reference